The importance of tau phosphorylation for neurodegenerative diseases

DOI: 10.3389/fneur.2013.00083
Frontiers in Neurology, 2013, 4, 83.

#	Paper	IF	Citations
263	Neurodegenerative lesions: seeding and spreading. **2013**, 169, 825-33		24
262	Cornel Iridoid Glycoside Attenuates Tau Hyperphosphorylation by Inhibition of PP2A Demethylation. **2013**, 2013, 108486		17
261	Derailed intraneuronal signalling drives pathogenesis in sporadic and familial Alzheimer's disease. **2014**, 2014, 167024		5
260	Impaired insulin signaling and mechanisms of memory loss. **2014**, 121, 413-49		31
259	Genetic markers for diagnosis and pathogenesis of Alzheimer's disease. **2014**, 545, 185-93		88
258	Biophysical challenges to axonal transport: motor-cargo deficiencies and neurodegeneration. **2014**, 43, 141-69		68
257	Acetylation: a new key to unlock tau's role in neurodegeneration. **2014**, 6, 29		82
256	"Tau oligomers," what we know and what we don't know. *Frontiers in Neurology*, **2014**, 5, 1	4.1	96
255	Protein phosphorylation in neurodegeneration: friend or foe?. **2014**, 7, 42		146
254	Integrated analysis of differential gene expression profiles in hippocampi to identify candidate genes involved in Alzheimer's disease. **2015**, 12, 6679-87		10
253	Physiologically relevant factors influence tau phosphorylation by leucine-rich repeat kinase 2. **2015**, 93, 1567-80		15
252	Imaging pathological tau in atypical parkinsonian disorders. **2015**, 28, 447-52		4
251	Tau Hyperphosphorylation and Oxidative Stress, a Critical Vicious Circle in Neurodegenerative Tauopathies?. **2015**, 2015, 151979		138
250	Further understanding of tau phosphorylation: implications for therapy. **2015**, 15, 115-22		33
249	Total tau is increased, but phosphorylated tau not decreased, in cerebrospinal fluid in amyotrophic lateral sclerosis. **2015**, 36, 1072-4		25
248	Tau-targeting passive immunization modulates aspects of pathology in tau transgenic mice. **2015**, 132, 135-45		57
247	Associations between primary open angle glaucoma, Alzheimer's disease and vascular dementia: record linkage study. **2015**, 99, 524-7		40

246	Distinct Neurodegenerative Changes in an Induced Pluripotent Stem Cell Model of Frontotemporal Dementia Linked to Mutant TAU Protein. **2015**, 5, 83-96		60
245	Neuronal Genes and Developmental Neuronal Pathways in Drosophila Life Span Control. **2015**, 3-37		4
244	5-HT(2C) serotonin receptor blockade prevents tau protein hyperphosphorylation and corrects the defect in hippocampal synaptic plasticity caused by a combination of environmental stressors in mice. **2015**, 99, 258-68		12
243	Biomarkers of Parkinson Disease. **2015**, 1009-1030		
242	New methods based on capillary electrophoresis for in vitro evaluation of protein tau phosphorylation by glycogen synthase kinase 3- **2015**, 407, 2821-8		11
241	Tau phosphorylation at serine 396 residue is required for hippocampal LTD. **2015**, 35, 4804-12		121
240	Invited review: Neuropathology of tauopathies: principles and practice. *Neuropathology and Applied Neurobiology*, **2015**, 41, 3-23	5.2	302
239	Small heat-shock proteins: important players in regulating cellular proteostasis. **2015**, 72, 429-451		138
238	Ameliorative Effects of Antioxidants on the Hippocampal Accumulation of Pathologic Tau in a Rat Model of Blast-Induced Traumatic Brain Injury. **2016**, 2016, 4159357		24
237	Neuropathology offrontotemporal dementia and related disorders. 165-184		1
236	Alzheimer disease: modeling an A centered biological network. **2016**, 21, 861-71		36
235	Clinical perspectives of TRAIL: insights into central nervous system disorders. **2016**, 73, 2017-27		27
234	Role of tau in the spatial organization of axonal microtubules: keeping parallel microtubules evenly distributed despite macromolecular crowding. **2016**, 73, 3745-60		26
233	Imatinib methanesulfonate reduces hyperphosphorylation of tau following repeated peripheral exposure to lipopolysaccharide. **2016**, 331, 72-7		14
232	Cdk5 at crossroads of protein oligomerization in neurodegenerative diseases: facts and hypotheses. **2016**, 136, 222-33		38
231	Tau and tauopathies. **2016**, 126, 238-292		292
230	Epidemiological pathology of Tau in the ageing brain: application of staging for neuropil threads (BrainNet Europe protocol) to the MRC cognitive function and ageing brain study. **2016**, 4, 11		32
229	Upregulation of calpain activity precedes tau phosphorylation and loss of synaptic proteins in Alzheimer's disease brain. **2016**, 4, 34		70

228	Hypothermia mediates age-dependent increase of tau phosphorylation in db/db mice. **2016**, 88, 55-65		28
227	Characterization of tau positron emission tomography tracer [F]AV-1451 binding to postmortem tissue in Alzheimer's disease, primary tauopathies, and other dementias. *Alzheimer's and Dementia*, **2016**, 12, 1116-1124	1.2	139
226	FLEXITau: Quantifying Post-translational Modifications of Tau Protein in Vitro and in Human Disease. **2016**, 88, 3704-14		74
225	Mislocalization of neuronal tau in the absence of tangle pathology in phosphomutant tau knockin mice. **2016**, 39, 1-18		17
224	Current and novel therapeutic molecules and targets in Alzheimer's disease. **2016**, 115, 3-10		87
223	A Quantitative Analysis of Brain Soluble Tau and the Tau Secretion Factor. **2017**, 76, 44-51		15
222	Impact of Phosphorylation and Pseudophosphorylation on the Early Stages of Aggregation of the Microtubule-Associated Protein Tau. **2017**, 121, 2095-2103		10
221	Positron emission tomography imaging of tau pathology in progressive supranuclear palsy. **2017**, 37, 3150-3160		38
220	Potential biomarkers and novel pharmacological targets in protein aggregation-related neurodegenerative diseases. **2017**, 131, 1-15		29
219	The neurotoxicity of amyloid protein oligomers is reversible in a primary neuron model. **2017**, 10, 4		30
218	Astrocyte pathology in a human neural stem cell model of frontotemporal dementia caused by mutant TAU protein. **2017**, 7, 42991		51
217	Tau phosphorylation induced by severe closed head traumatic brain injury is linked to the cellular prion protein. **2017**, 5, 30		39
216	Antioxidants reduce neurodegeneration and accumulation of pathologic Tau proteins in the auditory system after blast exposure. **2017**, 108, 627-643		21
215	Inhibition of the Aggregation and Toxicity of the Minimal Amyloidogenic Fragment of Tau by Its Pro-Substituted Analogues. **2017**, 23, 9618-9624		16
214	Roles of tau protein in health and disease. **2017**, 133, 665-704		415
213	Glycan Determinants of Heparin-Tau Interaction. **2017**, 112, 921-932		47
212	Molecular Dynamics Simulation of Tau Peptides for the Investigation of Conformational Changes Induced by Specific Phosphorylation Patterns. **2017**, 1523, 33-59		4
211	Inhibition of glycogen synthase kinase-3 by BTA-EG reduces tau abnormalities in an organotypic brain slice culture model of Alzheimer's disease. **2017**, 7, 7434		16

210	Phosphorylation of huntingtin at residue T3 is decreased in Huntington's disease and modulates mutant huntingtin protein conformation. **2017**, 114, E10809-E10818		33
209	models of tauopathy. **2017**, 31, 5137-5148		17
208	Isoelectric point-based fractionation by HiRIEF coupled to LC-MS allows for in-depth quantitative analysis of the phosphoproteome. **2017**, 7, 4513		15
207	Imaging tau pathology in Parkinsonisms. **2017**, 3, 22		11
206	mTOR and neuronal cell cycle reentry: How impaired brain insulin signaling promotes Alzheimer's disease. *Alzheimer's and Dementia*, **2017**, 13, 152-167	1.2	48
205	Cerebrospinal Fluid Progranulin, but Not Serum Progranulin, Is Reduced in GRN-Negative Frontotemporal Dementia. **2017**, 17, 83-88		18
204	Studying tau protein propagation and pathology in the mouse brain using adeno-associated viruses. **2017**, 141, 307-322		17
203	White matter tauopathy: Transient functional loss and novel myelin remodeling. **2018**, 66, 813-827		6
202	Preclinical, phase I, and phase II investigational clinical trials for treatment of progressive supranuclear palsy. **2018**, 27, 349-361		14
201	The physiological phosphorylation of tau is critically changed in fetal brains of individuals with Down syndrome. *Neuropathology and Applied Neurobiology*, **2018**, 44, 314-327	5.2	16
200	Tau can switch microtubule network organizations: from random networks to dynamic and stable bundles. **2018**, 29, 154-165		27
199	The Microtubule-Associated Protein Tau Mediates the Organization of Microtubules and Their Dynamic Exploration of Actin-Rich Lamellipodia and Filopodia of Cortical Growth Cones. **2018**, 38, 291-307		59
198	Functional significance of O-GlcNAc modification in regulating neuronal properties. **2018**, 129, 295-307		14
197	[Development of imaging-based diagnostic procedures for brain protein aging using a mouse model of tauopathy]. **2018**, 152, 4-9		
196	Different tau species lead to heterogeneous tau pathology propagation and misfolding. **2018**, 6, 132		50
195	MRI and histological evaluation of pulsed focused ultrasound and microbubbles treatment effects in the brain. **2018**, 8, 4837-4855		40
194	Alzheimer's disease (AD) therapeutics - 2: Beyond amyloid - Re-defining AD and its causality to discover effective therapeutics. **2018**, 158, 376-401		20
193	Novel Protein Kinase Inhibitors Related to Tau Pathology Modulate Tau Protein-Self Interaction Using a Luciferase Complementation Assay. **2018**, 23,		11

192	Novel monoclonal antibodies targeting the microtubule-binding domain of human tau. **2018**, 13, e0195211		10
191	Molecular Aspects of Concussion and Chronic Traumatic Encephalopathy. **2018**, 335-380		
190	Characterisation of tau in the human and rodent enteric nervous system under physiological conditions and in tauopathy. **2018**, 6, 65		14
189	Dendritic Tau in Alzheimer's Disease. **2018**, 99, 13-27		113
188	Inflammasome-derived cytokine IL18 suppresses amyloid-induced seizures in Alzheimer-prone mice. **2018**, 115, 9002-9007		19
187	Tau-targeting therapies for Alzheimer disease. **2018**, 14, 399-415		414
186	Targeting Neuroplasticity, Cardiovascular, and Cognitive-Associated Genomic Variants in Familial Alzheimer's Disease. *Molecular Neurobiology*, **2019**, 56, 3235-3243	6.2	5
185	Neurotrophin receptor p75 mediates amyloid induced tau pathology. **2019**, 132, 104567		21
184	Cholinesterase inhibitors as Alzheimer's therapeutics (Review). **2019**, 20, 1479-1487		130
183	LC3-Associated Endocytosis Facilitates Amyloid Clearance and Mitigates Neurodegeneration in Murine Alzheimer's Disease. **2019**, 178, 536-551.e14		184
182	Autophagy-Mediated Secretory Pathway is Responsible for Both Normal and Pathological Tau in Neurons. **2019**, 70, 667-680		23
181	Drugs for Targeted Therapies of Alzheimer's Disease. **2019**, 26, 335-359		9
180	Enhancement of tripartite synapses as a potential therapeutic strategy for Alzheimer's disease: a preclinical study in rTg4510 mice. **2019**, 11, 75		4
179	Interrogating Parkinson's disease associated redox targets: Potential application of CRISPR editing. **2019**, 144, 279-292		9
178	Disordered Expression of , the Gene Encoding a Serine-Threonine Protein Kinase GSK3, Affects the Lifespan in a Transcript-, Stage-, and Tissue-Specific Manner. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	5
177	Tau Protein and Zebrafish Models for Tau-Induced Neurodegeneration. **2019**, 69, 339-353		4
176	Tanshinone IIA Ameliorates Spatial Learning and Memory Deficits by Inhibiting the Activity of ERK and GSK-3**2019**, 32, 152-163		12
175	Modulation of aggregation with an electric field; scientific roadmap for a potential non-invasive therapy against tauopathies.. **2019**, 9, 4744-4750		12

174	Retrograde transport of Akt by a neuronal Rab5-APPL1 endosome. **2019**, 9, 2433		15
173	Endoplasmic Reticulum Stress in Tauopathies: Contrasting Human Brain Pathology with Cellular and Animal Models. **2019**, 68, 439-458		5
172	Cre-inducible Adeno Associated Virus-mediated Expression of P301L Mutant Tau Causes Motor Deficits and Neuronal Degeneration in the Substantia Nigra. **2019**, 422, 65-74		5
171	BDNF Val66Met Genetic Polymorphism Results in Poor Recovery Following Repeated Mild Traumatic Brain Injury in a Mouse Model and Treatment With AAV-BDNF Improves Outcomes. *Frontiers in Neurology*, **2019**, 10, 1175	4.1	11
170	Tau Biology, Tauopathy, Traumatic Brain Injury, and Diagnostic Challenges. **2019**, 67, 447-467		46
169	It's all about tau. **2019**, 175, 54-76		75
168	Phosphorylation of serine 305 in tau inhibits aggregation. **2019**, 692, 187-192		15
167	Electrochemical approaches for the detection of amyloid-β, tau, and α-synuclein. **2019**, 14, 89-95		7
166	GRK5 influences the phosphorylation of tau via GSK3β and contributes to Alzheimer's disease. **2019**, 234, 10411-10420		5
165	A distributed multitask multimodal approach for the prediction of Alzheimer's disease in a longitudinal study. **2020**, 206, 116317		11
164	Considerations for future tau-targeted therapeutics: can they deliver?. **2020**, 15, 265-267		9
163	From the prion-like propagation hypothesis to therapeutic strategies of anti-tau immunotherapy. **2020**, 139, 3-25		65
162	Aggregation of biologically important peptides and proteins: inhibition or acceleration depending on protein and metal ion concentrations.. **2019**, 10, 215-227		21
161	Heavy metal toxicity and the aetiology of glaucoma. **2020**, 34, 129-137		5
160	Key Physicochemical and Biological Factors of the Phase Behavior of Tau. **2020**, 6, 2924-2963		2
159	Hyperphosphorylated tau aggregation and cytotoxicity modulators screen identified prescription drugs linked to Alzheimer's disease and cognitive functions. **2020**, 10, 16551		10
158	Cellular Biology of Tau Diversity and Pathogenic Conformers. *Frontiers in Neurology*, **2020**, 11, 590199	4.1	7
157	Serum Tau Proteins as Potential Biomarkers for the Assessment of Alzheimer's Disease Progression. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	20

156	Targeting Tau to Treat Clinical Features of Huntington's Disease. *Frontiers in Neurology*, **2020**, 11, 580732	4.1	6
155	APOE4 genetic polymorphism results in impaired recovery in a repeated mild traumatic brain injury model and treatment with Bryostatin-1 improves outcomes. **2020**, 10, 19919		5
154	Tauopathies: Deciphering Disease Mechanisms to Develop Effective Therapies. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	15
153	Edible dairy formula fortified with coconut oil for neuroprotection against aluminium chloride-induced Alzheimer's disease in rats. **2020**, 75, 104296		6
152	Prion-Like Propagation Mechanisms in Tauopathies and Traumatic Brain Injury: Challenges and Prospects. **2020**, 10,		2
151	Flexibility Is Costly: Hidden Physiological Damage From Seasonal Phenotypic Transitions in Heterothermic Species. **2020**, 11, 985		3
150	PHF-Core Tau as the Potential Initiating Event for Tau Pathology in Alzheimer's Disease. **2020**, 14, 247		7
149	Huang-Pu-Tong-Qiao Formula Ameliorates Tau Phosphorylation by Inhibiting the CaM-CaMKIV Pathway. **2020**, 2020, 8956071		2
148	An Overview of Astrocyte Responses in Genetically Induced Alzheimer's Disease Mouse Models. **2020**, 9,		8
147	□Synuclein and tau, two targets for dementia. **2020**, 67, 1-25		2
146	Pathway Analysis for Plasma □Amyloid, Tau and Neurofilament Light (ATN) in World Trade Center Responders at Midlife. **2020**, 9, 159-171		15
145	Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer's disease and PET amyloid-positive patient identification. **2020**, 12, 26		80
144	Brain microRNAs dysregulation: Implication for missplicing and abnormal post-translational modifications of tau protein in Alzheimer's disease and related tauopathies. **2020**, 155, 104729		10
143	Recent Preclinical Insights Into the Treatment of Chronic Traumatic Encephalopathy. **2020**, 14, 616		1
142	Potential Bidirectional Relationship Between Periodontitis and Alzheimer's Disease. **2020**, 11, 683		14
141	Multiphosphorylated peptides: importance, synthetic strategies, and applications for studying biological mechanisms. **2020**, 18, 3405-3422		8
140	P301 L, an FTDP-17 Mutant, Exhibits Enhanced Glycation in vitro. **2020**, 75, 61-71		
139	Multifunctional compounds for the treatment of Alzheimer□ disease. **2021**, 99, 1-9		4

138	Disrupted ubiquitin proteasome system underlying tau accumulation in Alzheimer's disease. **2021**, 99, 79-85		4
137	Interplay of isoform 1N4R tau protein and amyloid-β peptide fragment 25-35 in reducing and non-reducing conditions. **2021**, 169, 119-134		0
136	Mesenchymal stem cell-derived extracellular vesicles ameliorate Alzheimer's disease-like phenotypes in a preclinical mouse model. **2021**, 11, 8129-8142		13
135	Similarities and Differences in the Pattern of Tau Hyperphosphorylation in Physiological and Pathological Conditions: Impacts on the Elaboration of Therapies to Prevent Tau Pathology. *Frontiers in Neurology*, **2020**, 11, 607680	4.1	5
134	Tau Post-translational Modifications: Dynamic Transformers of Tau Function, Degradation, and Aggregation. *Frontiers in Neurology*, **2020**, 11, 595532	4.1	37
133	Conformational fingerprinting of tau variants and strains by Raman spectroscopy. **2021**, 11, 8899-8915		4
132	Journey on Naphthoquinone and Anthraquinone Derivatives: New Insights in Alzheimer's Disease. **2021**, 14,		18
131	Sustained Interleukin-1β overexpression exacerbates Tau pathology in a murine tauopathy model via cyclooxygenase-1.		
130	Imaging Techniques in Alzheimer's Disease: A Review of Applications in Early Diagnosis and Longitudinal Monitoring. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	13
129	Cognitive Improvement and Safety Assessment of a Dietary Supplement Containing Propolis Extract in Elderly Japanese: A Placebo-Controlled, Randomized, Parallel-Group, Double-Blind Human Clinical Study. **2021**, 2021, 6664217		4
128	A common theme for axonopathies? The dependency cycle of local axon homeostasis. **2021**, 78, 52-63		2
127	Kinase Signaling in Dendritic Development and Disease. **2021**, 15, 624648		4
126	GSK-3 and Tau: A Key Duet in Alzheimer's Disease. **2021**, 10,		26
125	Impact of chronic hyperglycemia on Small Heat Shock Proteins in diabetic rat brain. **2021**, 701, 108816		3
124	Dysfunctional vascular smooth muscle cells mediate early and late-stage neuroinflammation and Tau hyperphosphorylation.		0
123	High-fat diet-induced activation of SGK1 promotes Alzheimer's disease-associated tau pathology. **2021**, 30, 1693-1710		5
122	SH-SY5Y-derived neurons: a human neuronal model system for investigating TAU sorting and neuronal subtype-specific TAU vulnerability. **2021**,		8
121	Subchronic exposure to acrylamide caused behaviour disorders and related pathological and molecular changes in rat cerebellum. **2021**, 340, 23-32		3

120	Prolonged arsenic exposure increases tau phosphorylation in differentiated SH-SY5Y cells: The contribution of GSK3 and ERK1/2. **2021**, 84, 103626		8
119	A Tau-Driven Adverse Outcome Pathway Blueprint Toward Memory Loss in Sporadic (Late-Onset) Alzheimer's Disease with Plausible Molecular Initiating Event Plug-Ins for Environmental Neurotoxicants. **2021**, 81, 459-485		3
118	Graph Models of Pathology Spread in Alzheimer's Disease: An Alternative to Conventional Graph Theoretic Analysis. **2021**, 11, 799-814		2
117	Inclusion of the C-Terminal Domain in the Sheet Core of Heparin-Fibrillized Three-Repeat Tau Protein Revealed by Solid-State Nuclear Magnetic Resonance Spectroscopy. **2021**, 143, 7839-7851		4
116	Alzheimer's Disease Animal Models: Elucidation of Biomarkers and Therapeutic Approaches for Cognitive Impairment. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	6
115	Oral (-)-Epicatechin Inhibits Progressive Tau Pathology in rTg4510 Mice Independent of Direct Actions at GSK3**2021**, 15, 697319		0
114	The Association between Tau Protein Level in Cerebrospinal Fluid and Cognitive Status: A Large-Scale Analysis of GAAIN Database. **2021**, 11,		2
113	Dichotomous role of microtubule associated protein tau as a biomarker of response to and a target for increasing efficacy of taxane treatment in cancers of epithelial origin. **2021**, 168, 105585		2
112	Intravenous administration of mesenchymal stem cells reduces Tau phosphorylation and inflammation in the 3xTg-AD mouse model of Alzheimer's disease. **2021**, 341, 113706		7
111	The Synaptic Vesicle Protein 2A Interacts With Key Pathogenic Factors in Alzheimer's Disease: Implications for Treatment. **2021**, 9, 609908		2
110	The potential role of glial cells in driving the prion-like transcellular propagation of tau in tauopathies. **2021**, 14, 100242		3
109	Metformin protects against neuroinflammation through integrated mechanisms of miR-141 and the NF-B-mediated inflammasome pathway in a diabetic mouse model. **2021**, 903, 174146		3
108	Relevance of 5-HT Receptor Modulation of Pyramidal Cell Excitability for Dementia-Related Psychosis: Implications for Pharmacotherapy. **2021**, 35, 727-741		5
107	The PI3K/Akt signaling axis in Alzheimer's disease: a valuable target to stimulate or suppress?. **2021**, 26, 871-887		11
106	Generation and characterization of a tractable C. elegans model of tauopathy. **2021**, 43, 2621-2631		0
105	Bushen-Huatan-Yizhi formula reduces spatial learning and memory challenges through inhibition of the GSK-3/CREB pathway in AD-like model rats. **2021**, 90, 153624		0
104	Transgenic fluorescent zebrafish lines that have revolutionized biomedical research. *Laboratory Animal Research*, **2021**, 37, 26	1.9	2
103	The role of neuroglial metabotropic glutamate receptors in Alzheimer's disease. **2021**,		2

102	Exendin-4 Improves Cognitive Function of Diabetic Mice via Increasing Brain Insulin Synthesis. **2021**, 18, 546-557		0
101	An Overview of the Nrf2/ARE Pathway and Its Role in Neurodegenerative Diseases. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	6
100	Activity-dependent release of phosphorylated human tau from Drosophila neurons in primary culture. **2021**, 297, 101108		0
99	Icariin ameliorate Alzheimer's disease by influencing SIRT1 and inhibiting A cascade pathogenesis. **2021**, 117, 102014		1
98	Tau peptide signals are seen in Parkinson subjects by Broderick Probe sensors. **2021**, 11, 46-50		
97	Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification. *Alzheimer's and Dementia*, **2021**, 17, 1365-1382	1.2	11
96	Knockdown of long non-coding RNA SOX21-AS1 attenuates amyloid- induced neuronal damage by sponging miR-107. **2020**, 40,		8
95	Evidence for sortilin modulating regional accumulation of human tau prions in transgenic mice. **2017**, 114, E11029-E11036		13
94	New advances in tau imaging in parkinsonism. **2017**, 29, 628-635		4
93	High-fat diet-induced activation of SGK1 promotes Alzheimer disease-associated tau pathology.		1
92	SIRT1 regulates O-GlcNAcylation of tau through OGT. **2020**, 12, 7042-7055		6
91	PTML Modeling for Alzheimer's Disease: Design and Prediction of Virtual Multi-Target Inhibitors of GSK3B, HDAC1, and HDAC6. **2020**, 20, 1661-1676		7
90	Current Therapeutic Molecules and Targets in Neurodegenerative Diseases Based on in silico Drug Design. **2018**, 16, 649-663		17
89	Racemization Hypothesis of COVID-19. Tip of the Iceberg.		1
88	Degradation or aggregation: the ramifications of post-translational modifications on tau. **2018**, 51, 265-273		31
87	Biomarkers of Parkinson Disease. **2014**, 1-18		
86	Retrograde transport of Akt by a neuronal Rab5-APPL1 endosome.		
85	Association of cellular and subcellular calcification with phosphorylated tau in the brains of Alzheimer disease patients.		

84	Arginine and Arginine-Rich Peptides as Modulators of Protein Aggregation and Cytotoxicity Associated With Alzheimer's Disease. **2021**, 14, 759729		3
83	New insights into the role of fibroblast growth factors in Alzheimer's disease. **2021**, 1		2
82	Post-translational modifications within tau paired helical filament nucleating motifs perturb microtubule interactions and oligomer formation. **2021**, 101442		1
81	Role of Oxygen Radicals in Alzheimer Disease: Focus on Tau Protein. **2021**, 1, 96-120		0
80	The role of pathological tau in synaptic dysfunction in Alzheimer's diseases. **2021**, 10, 45		6
79	Human Induced Pluripotent Stem Cell Models of Frontotemporal Dementia With Tau Pathology. **2021**, 9, 766773		0
78	Nanotechnology: An Emerging Field in Protein Aggregation and Cancer Therapeutics. **2022**, 177-207		
77	Human Genome-wide Analysis and Identification of the Hyperphosphorylation-elicited Interactions between Subarachnoid Tau Protein and Phosphoprotein-binding Domains. **2021**,		1
76	Comparative Analysis of Aducanumab, Zagotenemab and Pioglitazone as Targeted Treatment Strategies for Alzheimer's Disease. **2021**, 12, 1964-1976		8
75	Synapses, Microglia, and Lipids in Alzheimer's Disease.. **2021**, 15, 778822		2
74	Quantitative Phosphoproteomics Reveals Extensive Protein Phosphorylation Dysregulation in the Cerebral Cortex of Huntington's Disease Mice Prior to Onset of Symptoms.. *Molecular Neurobiology* , **2022**, 59, 2456	6.2	1
73	Amyloid-beta peptide and tau protein crosstalk in Alzheimer's disease.. **2022**, 17, 1666-1674		9
72	Fukutin regulates tau phosphorylation and synaptic function: Novel properties of fukutin in neurons.. **2022**,		2
71	Tanshinone IIA regulates glycogen synthase kinase-3 related signaling pathway and ameliorates memory impairment in APP/PS1 transgenic mice.. **2022**, 174772		0
70	Neuroimaging (Anatomical MRI)-Based Classification of Alzheimer Diseases and Mild Cognitive Impairment Using Convolution Neural Network. **2022**, 77-87		
69	Glycogen Synthase Kinase 3 Involvement in Neuroinflammation and Neurodegenerative Diseases.. **2022**,		1
68	The Effect of Lipid Composition on the Dynamics of Tau Fibrils.		
67	Tau liquid-liquid phase separation in neurodegenerative diseases.. **2022**,		6

66	Nuclear and cellular, micro and nano calcification in Alzheimer's disease patients and correlation to phosphorylated Tau.. **2022**,		3
65	Proteomic analysis of heat-stable proteins revealed an increased proportion of proteins with compositionally biased regions.. **2022**, 12, 4347		0
64	Neuroprotective Effects of Cholinesterase Inhibitors: Current Scenario in Therapies for Alzheimer's Disease and Future Perspectives.. *Journal of Alzheimer's Disease Reports*, **2022**, 6, 177-193	3.3	1
63	Targeting tau only extracellularly is likely to be less efficacious than targeting it both intra- and extracellularly.. *Seminars in Cell and Developmental Biology*, **2021**,	7.5	0
62	Differential expression of tau species and the association with cognitive decline and synaptic loss in Alzheimer's disease. *Alzheimer's and Dementia*, **2021**,	1.2	1
61	Alzheimer: A Complex Genetic Background.		
60	Perspectives on the Role of as a Therapeutic Target for Alzheimer's Disease.. *Journal of Alzheimer's Disease Reports*, **2021**, 5, 899-910	3.3	
59	Tauopathies. 109-148		1
58	Image_1.TIF. **2019**,		
57	Image_2.TIF. **2019**,		
56	Image_3.TIF. **2019**,		
55	Image_4.TIF. **2019**,		
54	Image_5.TIF. **2019**,		
53	Table_1.docx. **2019**,		
52	GSK-3 and its Inhibitors in Alzheimer's Disease: A Recent Update.. *Mini-Reviews in Medicinal Chemistry*, **2022**,	3.2	0
51	Contributive Role of Hyperglycemia and Hypoglycemia Towards the Development of Alzheimer's Disease.. *Molecular Neurobiology*, **2022**, 1	6.2	2
50	Retinoic acid regulates the ubiquitin-proteasome system in a middle cerebral artery occlusion animal model.. *Laboratory Animal Research*, **2022**, 38, 13	1.9	0
49	The LPA-CDK5-tau pathway mediates neuronal injury in an in vitro model of ischemia-reperfusion insult.. *BMC Neurology*, **2022**, 22, 166	3.1	0

48	Tau acetylation at K280 regulates tau phosphorylation. *International Journal of Neuroscience*, 1-7	2	0
47	Metformin: Is it a drug for all reasons and diseases?. *Metabolism: Clinical and Experimental*, **2022**, 155223	12.7	6
46	Tau R2 and R3 are essential regions for tau aggregation, seeding and propagation. *Biochimie*, **2022**, 200, 79-86	4.6	0
45	Tau-aggregation inhibition: promising role of nanoencapsulated dietary molecules in the management of Alzheimer's disease. *Critical Reviews in Food Science and Nutrition*, 1-16	11.5	
44	Investigating key factors underlying neurodegeneration linked to alpha-synuclein spread. *Neuropathology and Applied Neurobiology*,	5.2	
43	Comprehensive Characterization of CK1-Mediated Tau Phosphorylation in Alzheimer's Disease. *Frontiers in Molecular Biosciences*, 9,	5.6	
42	Site-specific C-terminal fluorescent labeling of Tau protein.		
41	Tau as a Biomarker of Neurodegeneration. *International Journal of Molecular Sciences*, **2022**, 23, 7307	6.3	4
40	Altered amyloid precursor protein, tau-regulatory proteins, neuronal numbers and behaviour, but no tau pathology, synaptic and inflammatory changes or memory deficits, at 1 month following repetitive mild traumatic brain injury. *European Journal of Neuroscience*,	3.5	0
39	A low-cost, flexible extruder for liposomes synthesis and application for Murrayafoline A delivery for cancer treatment. *Journal of Biomaterials Applications*, 088532822211124	2.9	1
38	Imaging Pathological Tau in Atypical Parkinsonisms: A Review. *Clinical Parkinsonism & Related Disorders*, **2022**, 100155	0.9	0
37	A and Tau Regulate Microglia Metabolism via Exosomes in Alzheimer's Disease. *Biomedicines*, **2022**, 10, 1800	4.8	0
36	Proteomic Assessment of C57BL/6 Hippocampi after Non-Selective Pharmacological Inhibition of Nitric Oxide Synthase Activity: Implications of Seizure-like Neuronal Hyperexcitability Followed by Tauopathy. *Biomedicines*, **2022**, 10, 1772	4.8	
35	Alzheimer's disease: Ablating single master site abolishes tau hyperphosphorylation. **2022**, 8,		0
34	Tau liquid–liquid phase separation: At the crossroads of tau physiology and tauopathy.		2
33	The effect of lipid composition on the dynamics of tau fibrils.		1
32	Glioblastoma is associated with extensive accelerated brain ageing.		
31	Title: Neuroprotective repositioning and anti-tau effect of carvedilol on rotenone induced neurotoxicity in rats: Insights from an insilico& in vivo anti-Parkinson's disease study. **2022**, 175204		0

30	The 28-day repeated arsenic exposure increases tau phosphorylation in the rat brain. **2022**, 95, 103974	0
29	Role of the Cysteine in R3 Tau Peptide in Copper Binding and Reactivity. **2022**, 23, 10726	1
28	Somatic Mutations and Alzheimer's Disease. **2022**, 1-18	0
27	More than a marker: potential pathogenic functions of MAP2. 15,	0
26	Molecular diagnosis of Alzheimer's disease. 14, 287-295	0
25	The Interplay between GSK3β and Tau Ser262 Phosphorylation during the Progression of Tau Pathology. **2022**, 23, 11610	0
24	Multiple Functions of Fukutin, the Gene Responsible for Fukuyama Congenital Muscular Dystrophy, Especially in the Central Nervous System.	0
23	Phosphorylated Tau in Alzheimer's Disease and Other Tauopathies. **2022**, 23, 12841	3
22	Liquid–liquid phase separation in neurodegenerative diseases. **2023**, 619-650	0
21	Modeling Alzheimer's Disease Using Human Brain Organoids. **2023**, 135-158	0
20	Dual action of exosomes derived from in vitro Aβ toxicity model: The role of age for pathological response. **2023**, 106, 104874	0
19	JUNupregulation drives aberrant transposable element mobilization, associated innate immune response, and impaired neurogenesis in Alzheimer's disease.	0
18	3-Hydroxy-3-methylglutaryl (HMG)-coenzyme A (CoA) reductase inhibitor modulates biomarkers related to Alzheimer's disease pathology in a sepsis-surviving rat model.	0
17	Ensemble Model for Diagnostic Classification of Alzheimer's Disease Based on Brain Anatomical Magnetic Resonance Imaging. **2022**, 12, 3193	1
16	Site-Specific C-Terminal Fluorescent Labeling of Tau Protein. **2022**, 7, 47009-47014	0
15	Role of Tau in Various Tauopathies, Treatment Approaches, and Emerging Role of Nanotechnology in Neurodegenerative Disorders.	0
14	The role of altered protein acetylation in neurodegenerative disease. 14,	0
13	The TgF344-AD rat: behavioral and proteomic changes associated with aging and protein expression in a transgenic rat model of Alzheimer's disease. **2023**, 123, 98-110	0

12	Pharmacotherapy Evolution in Alzheimer Disease: Current Framework and Relevant Directions. **2023**, 12, 131	1
11	Separation of Isomeric Tau Phosphopeptides from Alzheimer Disease Brain by Cyclic Ion Mobility Mass Spectrometry.	0
10	The Effect of the Tau Protein on D. melanogaster Lifespan Depends on GSK3 Expression and Sex. **2023**, 24, 2166	0
9	Tau, tau kinases, and tauopathies: An updated overview.	0
8	Initiation and modulation of Tau protein phase separation by the drug suramin. **2023**, 13,	0
7	Friend or foe: role of pathological tau in neuronal death.	0
6	Diagnostic Role of Tau Proteins in Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis. **2023**, 2023, 1-10	0
5	Deep Learning to Detect the Function of Calmodulin in Alzheimer Disease. 36, 720-725	0
4	Epigenetic regulons in Alzheimer's disease. **2023**,	0
3	Tau positron emission tomography in tauopathies: A narrative review. **2023**, 7, 7-24	0
2	A prolyl oligopeptidase inhibitor reduces tau pathology in cellular models and in mice with tauopathy. **2023**, 15,	0
1	Domain-specific modulatory effects of phosphomimetic substitutions on liquid-liquid phase separation of tau protein. **2023**, 104722	0